Latest Content

Clinicians weigh benzodiazepine benefits against dependence fears, with expert guidance on safe prescribing, withdrawal tapering, and long-term anxiety treatment choices.

A psychotherapist recommends standout books that help artists face doubt, master practice, and protect vision—insightful guidance across mediums.

See the latest in this psychiatric news roundup.

FDA clears a simple pTau217 blood test that helps clinicians rule in or out Alzheimer’s amyloid earlier, expanding access beyond PET/CSF.

In this CME article, explore why migraine often coexists with depression and anxiety, and get practical tips for diagnosis, prevention, and smarter prescribing.

Clearmind patents MDMA plus PEA combo aiming to boost PTSD, anxiety and eating-disorder therapy as FDA issues new psychedelic trial guidance.

FDA acceptance of mitragynine IND launches NIH phase 1 trial for opioid use disorder, tracking safety, dosing, and PK amid new DEA scheduling moves.

Digital reading boosts convenience but weakens comprehension and memory; evidence links “digital amnesia” to shallower learning, making print vital for deep clinical study.

PleoPharma secures $6.5M NIDA grant to advance phase 3 PP-01 trial, aiming to ease cannabis withdrawal and address untreated cannabis use disorder.

Long-acting injectable buprenorphine cuts missed doses, boosts retention, and protects patients during high-risk transitions in the fentanyl era.

FDA signals clear IND path for PT00114, a first-in-class neuropeptide aiming to reset stress responses in patients with generalized anxiety disorder.

Urine drug screenings are often misordered and misread, risking stigma and harm; learn immunoassay limits, confirmatory testing basics, and when testing truly helps.

FDA clears a Parkinson disease wearable and fast-tracks ecopipam for pediatric Tourette syndrome, showing advances in neuropsychiatric care.